Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: MAP3K7

Gene summary for MAP3K7

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

MAP3K7

Gene ID

6885

Gene namemitogen-activated protein kinase kinase kinase 7
Gene AliasCSCF
Cytomap6q15
Gene Typeprotein-coding
GO ID

GO:0000165

UniProtAcc

O43318


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
6885MAP3K7LZE4THumanEsophagusESCC1.54e-072.39e-010.0811
6885MAP3K7LZE7THumanEsophagusESCC5.56e-093.83e-010.0667
6885MAP3K7LZE8THumanEsophagusESCC1.02e-041.33e-010.067
6885MAP3K7LZE20THumanEsophagusESCC3.39e-041.62e-010.0662
6885MAP3K7LZE24THumanEsophagusESCC1.15e-133.60e-010.0596
6885MAP3K7LZE21THumanEsophagusESCC3.07e-022.44e-010.0655
6885MAP3K7P2T-EHumanEsophagusESCC2.65e-183.59e-010.1177
6885MAP3K7P4T-EHumanEsophagusESCC2.15e-132.74e-010.1323
6885MAP3K7P5T-EHumanEsophagusESCC5.59e-121.35e-010.1327
6885MAP3K7P8T-EHumanEsophagusESCC1.07e-132.81e-010.0889
6885MAP3K7P9T-EHumanEsophagusESCC6.14e-041.43e-010.1131
6885MAP3K7P10T-EHumanEsophagusESCC6.82e-203.22e-010.116
6885MAP3K7P11T-EHumanEsophagusESCC2.60e-155.18e-010.1426
6885MAP3K7P12T-EHumanEsophagusESCC8.10e-153.96e-010.1122
6885MAP3K7P15T-EHumanEsophagusESCC1.07e-163.27e-010.1149
6885MAP3K7P16T-EHumanEsophagusESCC9.28e-255.40e-010.1153
6885MAP3K7P17T-EHumanEsophagusESCC2.88e-063.51e-010.1278
6885MAP3K7P19T-EHumanEsophagusESCC4.06e-094.13e-010.1662
6885MAP3K7P20T-EHumanEsophagusESCC3.32e-061.06e-010.1124
6885MAP3K7P21T-EHumanEsophagusESCC4.24e-194.80e-010.1617
Page: 1 2 3 4 5 6 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:000724925SkincSCCI-kappaB kinase/NF-kappaB signaling116/4864281/187231.33e-084.08e-07116
GO:004312225SkincSCCregulation of I-kappaB kinase/NF-kappaB signaling105/4864249/187231.70e-085.09e-07105
GO:001050619SkincSCCregulation of autophagy127/4864317/187232.36e-086.71e-07127
GO:003052227SkincSCCintracellular receptor signaling pathway108/4864265/187239.21e-082.21e-06108
GO:000647314SkincSCCprotein acetylation84/4864201/187236.94e-071.29e-0584
GO:00162419SkincSCCregulation of macroautophagy63/4864141/187231.13e-061.97e-0563
GO:001839414SkincSCCpeptidyl-lysine acetylation72/4864169/187231.81e-063.02e-0572
GO:001820515SkincSCCpeptidyl-lysine modification137/4864376/187234.09e-066.09e-05137
GO:004354314SkincSCCprotein acylation95/4864243/187234.56e-066.71e-0595
GO:000647514SkincSCCinternal protein amino acid acetylation66/4864160/187231.72e-052.07e-0466
GO:001839314SkincSCCinternal peptidyl-lysine acetylation65/4864158/187232.19e-052.54e-0465
GO:001657313SkincSCChistone acetylation62/4864152/187234.54e-054.75e-0462
GO:007155917SkincSCCresponse to transforming growth factor beta95/4864256/187235.21e-055.31e-0495
GO:003109825SkincSCCstress-activated protein kinase signaling cascade92/4864247/187235.78e-055.74e-0492
GO:007156025SkincSCCcellular response to transforming growth factor beta stimulus92/4864250/187239.65e-058.99e-0492
GO:005140325SkincSCCstress-activated MAPK cascade88/4864239/187231.32e-041.20e-0388
GO:007190024SkincSCCregulation of protein serine/threonine kinase activity123/4864359/187232.70e-042.17e-03123
GO:000283122SkincSCCregulation of response to biotic stimulus112/4864327/187235.00e-043.76e-03112
GO:000275322SkincSCCcytoplasmic pattern recognition receptor signaling pathway27/486460/187231.10e-037.24e-0327
GO:000725423SkincSCCJNK cascade60/4864167/187232.77e-031.56e-0260
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa05132211EsophagusESCCSalmonella infection191/4205249/84656.51e-195.45e-172.79e-17191
hsa05169210EsophagusESCCEpstein-Barr virus infection151/4205202/84651.55e-133.45e-121.77e-12151
hsa05418211EsophagusESCCFluid shear stress and atherosclerosis109/4205139/84652.00e-123.72e-111.90e-11109
hsa05131211EsophagusESCCShigellosis176/4205247/84652.27e-124.01e-112.05e-11176
hsa05130211EsophagusESCCPathogenic Escherichia coli infection142/4205197/84658.21e-111.06e-095.42e-10142
hsa0466810EsophagusESCCTNF signaling pathway89/4205114/84653.36e-104.01e-092.06e-0989
hsa05170210EsophagusESCCHuman immunodeficiency virus 1 infection147/4205212/84653.37e-093.53e-081.81e-08147
hsa0513526EsophagusESCCYersinia infection100/4205137/84651.80e-081.59e-078.12e-08100
hsa05171211EsophagusESCCCoronavirus disease - COVID-19156/4205232/84653.18e-082.68e-071.37e-07156
hsa0414010EsophagusESCCAutophagy - animal101/4205141/84657.60e-086.21e-073.18e-07101
hsa05417211EsophagusESCCLipid and atherosclerosis143/4205215/84653.30e-072.45e-061.26e-06143
hsa0452030EsophagusESCCAdherens junction69/420593/84651.08e-066.83e-063.50e-0669
hsa051619EsophagusESCCHepatitis B108/4205162/84657.68e-064.15e-052.12e-05108
hsa0465727EsophagusESCCIL-17 signaling pathway66/420594/84653.93e-051.75e-048.99e-0566
hsa0514525EsophagusESCCToxoplasmosis76/4205112/84656.83e-052.90e-041.48e-0476
hsa0415210EsophagusESCCAMPK signaling pathway80/4205121/84651.73e-046.67e-043.42e-0480
hsa051629EsophagusESCCMeasles90/4205139/84652.16e-047.87e-044.03e-0490
hsa0462122EsophagusESCCNOD-like receptor signaling pathway116/4205186/84652.90e-041.03e-035.30e-04116
hsa040645EsophagusESCCNF-kappa B signaling pathway67/4205104/84651.62e-034.89e-032.50e-0367
hsa046607EsophagusESCCT cell receptor signaling pathway63/4205104/84651.60e-023.60e-021.84e-0263
Page: 1 2 3 4 5 6 7 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
MAP3K7SNVMissense_Mutationrs758224984c.821G>Ap.Arg274Hisp.R274HO43318protein_codingdeleterious(0)probably_damaging(1)TCGA-AN-A046-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
MAP3K7SNVMissense_Mutationc.919G>Ap.Glu307Lysp.E307KO43318protein_codingtolerated(0.22)benign(0.013)TCGA-BH-A0DZ-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapydocetaxelSD
MAP3K7SNVMissense_Mutationnovelc.1745N>Gp.Ser582Cysp.S582CO43318protein_codingtolerated(0.08)possibly_damaging(0.908)TCGA-LD-A74U-01Breastbreast invasive carcinomaFemale>=65III/IVChemotherapytaxotereSD
MAP3K7insertionFrame_Shift_Insnovelc.1670_1671insAAATAAACAAp.Asp557GlufsTer5p.D557Efs*5O43318protein_codingTCGA-AR-A0U0-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
MAP3K7SNVMissense_Mutationc.217N>Tp.Ala73Serp.A73SO43318protein_codingdeleterious(0)benign(0.176)TCGA-AA-3710-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
MAP3K7SNVMissense_Mutationc.49N>Ap.Glu17Lysp.E17KO43318protein_codingtolerated_low_confidence(0.15)benign(0.017)TCGA-AZ-6599-01Colorectumcolon adenocarcinomaMale>=65I/IIUnknownUnknownSD
MAP3K7SNVMissense_Mutationc.1754A>Gp.Tyr585Cysp.Y585CO43318protein_codingtolerated(0.27)benign(0)TCGA-CK-5913-01Colorectumcolon adenocarcinomaFemale<65I/IIUnknownUnknownSD
MAP3K7SNVMissense_Mutationrs762121500c.1237N>Tp.Arg413Cysp.R413CO43318protein_codingdeleterious(0.05)probably_damaging(0.973)TCGA-F4-6807-01Colorectumcolon adenocarcinomaFemale<65III/IVChemotherapyxelodaCR
MAP3K7SNVMissense_Mutationnovelc.197N>Gp.Glu66Glyp.E66GO43318protein_codingdeleterious(0)benign(0.25)TCGA-AG-A002-01Colorectumrectum adenocarcinomaMale<65I/IIUnknownUnknownSD
MAP3K7SNVMissense_Mutationc.673C>Tp.Arg225Cysp.R225CO43318protein_codingdeleterious(0.02)probably_damaging(0.963)TCGA-A5-A0VP-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
Page: 1 2 3 4 5 6 7 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
6885MAP3K7ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTORinhibitor329968393
6885MAP3K7ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTORinhibitor223366077RGB-286638
6885MAP3K7ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTORinhibitor348353658
6885MAP3K7ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTORinhibitor249565754
6885MAP3K7ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTORinhibitor348353615
6885MAP3K7ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTORinhibitor249565876
6885MAP3K7ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTORinhibitor249565757CHEMBL1077979
6885MAP3K7ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTORinhibitor348353659
6885MAP3K7ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTORinhibitor249565869CEP-11981
Page: 1